DKA FINANS ApS: Financial statements 2023
CVR: 26028906
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
DKA FINANS ApS (CVR 26028906) has filed annual accounts for 2023. In 2023, the company reported a net result of DKK -148,558 compared with DKK -122,475 the year before. Equity in the 2023 report amounted to DKK -3,943,356.
- Profit/Loss
- DKK -148,558
- Equity
- DKK -3,943,356
- Total Assets
- DKK 1,303
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | - | -149 t. | -3.9 mio. | - |
| 2022 | - | -1 | -122 t. | -3.8 mio. | - |
| 2021 | - | - | 6.2 mio. | -3.7 mio. | - |
| 2020 | - | - | -297 t. | -9.9 mio. | - |
| 2019 | - | - | -293 t. | -9.6 mio. | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
DKA FINANS ApS has published its annual report for 2022. Gross profit came to DKK -1, and the net result was DKK -122,475.
About DKA FINANS ApS
DKA FINANS ApS was a Danish company of the type Anpartsselskab based in Hørsholm, founded in 2001. The company has been dissolved on 25 September 2025. The company was registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named DKA PHARMA ApS and IMMUNOLEX THERAPEUTICS ApS. The company has 2 employees (2003). In 2024, the company reported a net result of DKK -140,083 compared with DKK -148,558 the year before. Equity in the 2024 report amounted to DKK -4,083,439.